Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997147 | 0.90 | RORC (0.48) | RORCBRD4CNR2PTGS1PTGS2 | |
| SCHEMBL4003566 | 0.85 | RORC (0.47) | RORCBRD4CNR2LMNAPTGS1 | |
| SCHEMBL4000252 | 0.81 | MEN1 (0.56) | RORCBRD4LMNAALDH1A1 | |
| SCHEMBL3997265 | 0.81 | KMT2A (0.54) | CNR2LMNAALDH1A1 | |
| SCHEMBL3995363 | 0.80 | BRD4 (0.55) | RORCBRD4CNR2PTGER4ALDH1A1 | |
| SCHEMBL3994829 | 0.79 | ALDH1A1 (0.51) | RORCBRD4CNR2PTGS1PTGS2 | |
| SCHEMBL1700398 | 0.77 | BRD4 (0.48) | RORCBRD4CNR2PTGS1PTGS2 | |
| SCHEMBL16035266 | 0.76 | PTGER4 (0.41) | CNR2PTGER4HDAC3HDAC1HDAC2 | |
| SCHEMBL3994377 | 0.76 | JAK2 (0.39) | BRD4CNR2PTGS1PTGS2LRRK2 | |
| SCHEMBL15068117 | 0.76 | BRD4 (0.44) | RORCBRD4CNR2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598393-B2 | Sulfonyl benzimidazole derivatives | PFIZER INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1809607-B1 | SULFONYL BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | KON-I KANA | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094750-A1 | Sulfonyl benzimidazole derivatives | TRPV1, CNR2, CNR1 | RORC 78/4885BRD4 207/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.